5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma

Bone Marrow Transplantation

Volumn 48, Issue 5, 2013, Pages 642-645

  Kushner, B H ^a   Modak, S ^a   Kramer, K ^a   Basu, E M ^a   Roberts, S S ^a   Cheung, N Kv ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

neuroblastoma; novel therapeutics; salvage therapy

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CEFIXIME; CYCLOPHOSPHAMIDE; ETOPOSIDE; INFUSION FLUID; IRINOTECAN; MESNA; TEMOZOLOMIDE;

ADOLESCENT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART FUNCTION; HEMORRHAGIC CYSTITIS; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NAUSEA; NEUROBLASTOMA; NEUTROPHIL COUNT; OUTPATIENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TUMOR VOLUME; VOMITING;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEUROBLASTOMA; OUTPATIENTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84877666198     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.202     Document Type: Article

References (20)

1. Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011; 4351-4357.
2. Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19: 3463-3469.
3. Kushner BH, Kramer K, Modak S, Cheung N-KV. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006; 24: 5271-5276.
4. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed highrisk neuroblastoma: a new approach to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2009; 27: 1290-1296.
5. Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 2003; 98: 2488-2494.
6. Simon T, Längler A, Berthold F, Klingebiel T, Hero B. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase-II trial. J Pediatr Hematol Oncol 2007; 29: 101-106.
7. Simon T, Längler A, Harnischmacher U, Frühwald MC, Jorch N, Claviez A et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of highrisk neuroblastoma: results of a phase-II trial. J Cancer Res Clin Oncol 2007; 133: 653-661.
8. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung N-KV. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004; 22: 4888-4892.
9. Kushner BH, Kramer K, Modak S, Yataghene K, Cheung N-KV. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. Eur J Cancer 2010; 47: 84-89.
10. Kushner BH, Kramer K, Modak S, Cheung N-KV. High-dose carboplatin-irinotecantemozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer 2011; 56: 403-408.
11. Kushner BH, Kramer K, Modak S, Qin L-X, Cheung N-KV. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer 2010; 116: 3054-3060.
12. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77.
13. Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neuro-Oncol 2010; 97: 409-418.
14. Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer 2002; 95: 1354-1365.
15. Pradhan KR, Johnson CS, Vik TA, Sender LS, Kreissman SG. A novel induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer 2006; 46: 793-802.
16. Grupp SA, Cohn SL, Wall D, Reynolds CP. Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day. Pediatr Blood Cancer 2006; 46: 719-722.
17. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approach to Neuroblastoma Therapy phase I study. J Clin Oncol 2009; 27: 1020-1025.
18. Kreissman SG, Rackoff W, Lee M, Breitfeld PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol/Oncol 1997; 19: 309-312.
19. Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R et al. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2010; 54: 596-602.
20. Strather D, Ashley D, Kellie SJ, Patel A, Jones-Wallace D, Thompson S et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001; 19: 2696-2704.